EMEA-002296-PIP01-17-M01

Invented name	Alunbrig
Active substance	brigatinib
Therapeutic area	Oncology
Decision number	P/0430/2019
PIP number	EMEA-002296-PIP01-17-M01
Pharmaceutical form(s)	Age-appropriate liquid dosage form Film-coated tablet
Condition(s) / indication(s)	Treatment of anaplastic large cell lymphoma Treatment of inflammatory myofibroblastic tumours
Route(s) of administration	Oral use
Contact for public enquiries	Takeda Pharm A/S Tel. +44 2031168000 E-mail: paediatrics@tgrd.com
Decision type	PM: decision on the application for modification of an agreed PIP

Add your rating

★ ★ ★ ★ ★